Fig. 3From: B7-H3 is eligible for predicting clinical outcomes in lung adenocarcinoma patients treated with EGFR tyrosine kinase inhibitorsKaplan-Meier survival curves of B7-H3 low/high LUAD patients treated with first-line EGFR-TKIs. A Progression-free survival. B Overall survivalBack to article page